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Abstract We cloned a novel isoform of presenilin I (presenilin 1- 
374) besides previously published presenilin 1-467 and 1-463 in 
human lymphocytes. Presenilin 1-463 was identical to presenilin 
1-467 except a 12 bp nucleotides deletion in its amino terminal 
region. Another isoform, presenilin 1-374 was produced by an 
alternative splicing with an additional exon consisting of 92 bp 
nucleotides (exon 11), which resulted in the frame shift with a 
stop codon to generate a truncated presenilin consisting of 374 
amino acids. The transcripts for presenilin 1-467/463 was 
ubiquitously detected while that for presenilin 1-374 was 
selectively detected in liver, spleen, kidney. Abnormal behavior 
of presenilin I on gel electrophoresis was found with affinity- 
purified antibodies against presenilin I. 
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1. Introduction 
Alzheimer's disease (AD) is a progressive intellectual failure 
with elderly people. The causal genes were identified as pre- 
senilin I ($182) on chromosome 14q24.3 [1], presenilin H 
(STM2 or E5-1) on chromosome lq31-42 [2,3] and APP on 
chromosome 21 [4-7] while apolipoprotein E allele e4 is estab- 
lished to be a risk factor located on chromosome 19 [8]. The 
biological function as well as protein-chemical property of 
presenil in I and II remain to be studied as urgent targets to 
understand AD pathogenesis. Here we prepared specific anti- 
bodies against presenilin I and examined the protein of pre- 
senilin I in in vitro translat ion product  using cDNA of pre- 
senilin L We found a new isoform of presenilin I and 
examined the biochemical nature of presenil in I on gel elec- 
trophoresis using three antibodies. The loop structure, the 
only hydrophil ic domain in presenil in I, was disturbed in 
the new presenil in I and discussed its regulatory function. 
2. Materials and methods 
2.1. cDNA isolation 
Total RNAs were prepared from peripheral white blood cells or 
frozen brain tissues by acid guanidine phenol-chloroform (AGPC) 
method [9]. Ten ~g of total RNAs were reverse-transcribed y Super- 
script II (Life Technologies) with XbaI-anchored specific primer, 
AD3#2 (5'-GCTCTAGACTAGATATAAAATTGATGGAA-3'). 
Full length presenilins were amplified from first strand templates using 
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LA PCR Kit (Takara Shuzo, Kyoto) with EcoRI-anchored primer, 
AD3#1 (5'-GCTCTAGAGAATTCGCTCCAATGACAGAGTTAC- 
CTG-3') and AD3#2 primer. PCR condition was 30 cycles of 20 s 
98°C, 30 s 54°C, and 8 min 68°C. EcoRIIXbaI restricted PCR pro- 
ducts were then recloned to Bluescript II and the nucleotide sequences 
were determined by dideoxy chain termination method with Seque- 
nase (Amersham, UK). 
2.2. Genome isolation 
The genomic fragment containing exon 10, 11, and 12 was amplified 
from 1 ~tg of genomic DNA prepared from white blood cells of a 
Japanese healthy subject using LA PCR Kit with EcoRI-anchored 
primers: AD3#4 (5'-CGGAATTCGTGTGGTTGGTGAATATGG- 
CA-3') and AD3#5 (5'-CGGAATTCGAAAGTTCCTGGACAG- 
CAGCT-3'). PCR condition was 30 cycles of 20 s 98°C, 1 min 
55°C, and 10 min 72°C. A partially digested 6 kb EcoRI genomic 
fragment was recloned to Bluescript II. The genomic lone was then 
mapped by restriction enzyme digestions and the nucleotide sequences 
flanking exon 11 were determined using exon l 1-specific primers: 
AD3#6 (5'-AGCCTGTCTGCCTCCTG-3') and AD3#7 (5'- 
CCGTGGGCCTGCAGGCA-3'). 
2.3. RT-PCR analysis 
Total RNAs and first strand cDNAs were prepared from brain, 
heart, muscle, kidney, liver, and spleen of an autopsy case as de- 
scribed above. Presenilin 1-467, 1-463, and 1-374 were amplified 
from first strand templates using Taq polymerase (Toyobo, Tokyo) 
with AD3#1 and AD3#3 (5'-CCCTGGGGTCGTCCATTA-3') or 
AD3#4 and AD3#5 primers. The PCR condition was 35 cycles of 
1 min 95°C, 1 min 55°C, and 1 min 72°C. PCR products were digested 
by PstI, NcoI, or StyI and resolved on 5% polyacrylamide gel. 
2.4. Preparation of three antibodies against presenilin I 
Three different antibodies, AD3N, AD3L and AD3C were raised in 
rabbits by immunizing synthetic peptides as antigens. Synthetic pep- 
tides were chosen from an amino terminal region (DNRER- 
QEHNDRRSLGHPEPLSNGRPQ) of presenilin 1-467 for AD3N, a 
loop region (MAEGDPEAQRRVSKNSKYNAESTERESQDTV) of 
presenilin 1-467 for AD3L and a carboxyl terminal region (GLVFY- 
FATDYLVQPFMDQLAFHQFYI) of presenilin 1-467 for AD3C. 
The immunizing protocol was as described previously [10]. Polyclonal 
antibodies were purified by affinity-column conjugated with synthetic 
peptides. The specific antibodies were eluted by 0.1 M glycine buffer, 
pH 2.5 and neutralized quickly with 2 M Trizma. Absorption was 
performed by incubating an antiserum (24  Ixg) with synthetic peptide 
(10 p.g) in 10% calf serum in PBS at room temperature for 60 min. 
2.5. In vitro translation and immunoprecipitation 
In vitro products were generated from presenilin 1-467-BSK and 
presenilin 1-374~BSK as templates by TNT Reticulocyte lysate system 
(Promega, Madison, WI) with T7 RNA polymerase (Promega) and 
[zSS]methionine (>37 TBq/mmol, Amersham, UK). The products were 
mixed with either of antibodies overnight at 4°C and immunoprecipi- 
tated with Protein A Sepharose 4 Fast Flow (Pharmacia Biotech). The 
resultant immunoprecipitates were washed with RIPA buffer (0.1% 
SDS, 1% Triton X-100, 0.5% deoxycholic acid in 50 mM Tris-HC1, 
pH 7.6, 150 mM NaC1). The final immunoprecipitates were resolved 
on SDS-polyacrylamide g l. The gel was amplified by Amplify (Amer- 
sham), dried, and exposed to Kodak-XAR5 film for 24 h. 
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Fig. 1. Amino acid alignment among presenilin I isoforms and other presenilin members. The amino acid sequence (in single-letter code) of pre- 
senilin 1-467 (S182) has been aligned with those of presenilin 1-463, presenilin 1-374, presenilin II, and Sel-12 using Clustal method contained in 
Lasergene software package (DNASTAR);  dashes denote gaps that have been introduced to maximize the alignment. The sequences identical 
to those of presenilin 1-467 were shown by black boxes. The numbering of the sequences was based on the amino acid sequence of presenilin 1- 
476. Predicted TM domains are underlined. The nucleotide sequences of presenilin 1-463 and presenilin 1-374 have been deposited in GenBank 
under accession umbers of U40379 and U40380, respectively. 
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3. Results 
3.1. Isoforms of presenilin I 
Presenilin I cDNA was amplified from human peripheral 
blood cells and brains by RT-PCR using primers based on 
the published sequence [1]. We sequenced 9 clones and iden- 
tified 3 species of transcripts as shown in Fig. 1. A clone 
identical to published presenilin I was referred to as prese- 
nilin 1-467 according to the number of amino acid residues 
[1]. Presenilin 1-463 lacked 12 bp nucleotides in the amino 
terminal region, resulting in the deletion of VRSQ between 
the 26th and 29th amino acids sequence of presenilin 1-467 
as also documented recently [11]. Another clone, designated 
as presenilin 1-374 was found to contain the additional insert 
a 
sequence consisting of 92 bp nucleotides to generate a frame 
shift in the loop structure followed by a stop codon, which 
resulted in the shorter isoform consisting of 374 amino 
acids. 
3.2. Exon 11 
In order to identify and locate the additional exon in the 
genome, we cloned a 6 kb genomic locus spanning exon 10 
and the following exon. As shown in Fig. 2, we identified exon 
11 in that genomic locus and determined the flanking se- 
quence of exon 11, revealing that presenilin 1-374 was gener- 
ated by an alternative splicing. PCR-amplified presenilin 1-374 
was further verified by restriction enzyme digestions: PstI, 
NcoI, and StyI (Fig. 2c,d). 
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Fig. 2. Genomic organization of exon 10, 11, and 12 of presenilin I gene. a, Presenilin 1-467 and presenilin 1-374 are generated by an alterna- 
tive splicing of exon 11. Presenilin 1-374 showed the new stop codon (indicated by an asterisk) in exon 12 due to a frame shift generated by 
the insertion of exon 11. B, BamH1. b, Junctional sequences between exon 10 and exon 12 of presenilin 1-467 and between exon 10 and 11 or 
exon 11 and 12 of presenilin 1-374, which, shows a frame shift in presenilin 1-374. Boundary sequences between exon 11 and intron sequences 
are shown in the lower panel. Donor and acceptor sites for splice are underlined in the genomic sequence, c, Schematic representation f RT- 
PCR strategy for the detection of presenilin 1-374. d, Presenilin 1-374 amplified from non-AD brain was verified by restriction enzyme diges- 
tion; StyI, NcoI, and PstI. 
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Fig. 3. Characterization f presenilin 1-467 and presenilin 1-374. Two cDNA clones of presenilin 1-467 and -374 were in vitro translated in the 
presence of [35S]methionine and their products were immunoprecipitated by antibodies against he N-terminal region (AD3N), loop region 
(AD3L), and C-terminal region (AD3C) of presenilin 1-467. a, [35S]presenilin 1-467 was immunoprecipitated by all three antibodies. 
b, [35S]presenilin 1-374 was immunoprecipitated by AD3N and AD3L but not by AD3C (right panel). 
3.3. The gene products of  presenilin I 
To characterize the gene products of presenilin isoforms, we 
analyzed the in vitro translated products of presenilin 1-467 
and presenilin 1-374 by immunoprecipitations with antibodies 
against N-terminal, C-terminal, and loop sequence of preseni- 
lin 1-467. As clearly demonstrated in Fig. 3, presenilin 1-467 
was identified as a single band with Mr 43,000 by all three 
antibodies while presenilin 1-374 was identified as a single 
band with Mr 31,000 by antibodies against he N-terminal 
and loop sequences but not by antibody against he C-term- 
inal sequence. Thus, immunoprecipitated presenilins howed 
their abnormalities in electrophoretic mobility in SDS-polya- 
crylamide gel because they were found to move faster than the 
calculated Mr (52,202 and 42,290). Both gene products 
showed proteolytic fragments beside full-sized forms, suggest- 
ing the occurrence of an endoproteolytic cleavage (unpub- 
lished). When presenilin I were heat-treated, the molecular 
masses of presenilin 1-467 and presenilin 1-374 were observed 
as 74,000 and 65,000, respectively. Moreover, when both sam- 
ples were extensively incubated in a boiling bath, these bands 
were markedly decreased and detected on the gel top (manu- 
script in preparation). Such abnormal property of presenilin I 
was similar to those of some membrane proteins [12,13]. 
3.4. The tissue-specific expression of presenil& isoforms 
We next investigated the expression of 3 isoforms of pre- 
senilin I in various tissues by RT-PCR, showing that preseni- 
lin 1-463 and presenilin 1-467 were both ubiquitously tran- 
scribed in brain tissue and other tissues (Fig. 4a). Presenilin 
1-374, however, was selectively detected in liver, kidney, and 
spleen by RT-PCR analysis (Fig. 4b). 
4. Discussion 
These variations of gene expression among presenilin I iso- 
forms may reflect the temporal and tissue-specific expression 
of presenilin 1-467, presenilin 1-463 and presenilin 1-374. 
Although the biological significance of these isoforms remains 
to be studied, it is tempting to speculate that the truncated 
presenilin 1-374 may regulate the function of presenilin 1-467/ 
463 by forming a mosaic complex since these isoforms only 
differ in loop and C-terminal TM domain sequence (Figs. 1 
and 2). It is also likely that presenilin protein is vulnerable to 
protease digestion. Hence full-sized presenilin may be the min- 
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Fig. 4. Expression of presenilin 1-467, 1-463, and 1-374 in AD brains 
and tissues, a, Transcripts for presenilin 1-463 (164 bp) and preseni- 
lin 1-467 (176 bp) were ubiquitously detected in tissues, b, The tran- 
script for presenilin 1-467/463 (218 bp) was ubiquitously detected in 
tissues while the transcript for presenilin 1-374 (310 bp) with exon 
11 (92 bp) was selectively detected in kidney, liver, and spleen. 
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or species in brain tissues. Thus, abnormal gene expression of 
presenilin I such as presenilin 1-374 or another unknown dys- 
functioning mechanism on presenilin I may play a pathologi- 
cal role in sporadic AD. Levitan and Greenwald recently re- 
ported that Sel-12, a suppressor and/or enhancer with 467 
amino acids of lin-12/Notch, was identified to be a C. elegans 
homolog for human presenilin 1 [14]. Sequence alignment be- 
tween presenilin-467/463 and Sel-12 showed the well-conserved 
structure of seven transmembranous domains and some part 
of loop domain (Fig. 1). This strongly suggests the evolutional 
conservation of presenilin/Sel-12 family beyond species of or- 
ganisms. Moreover, a mutated allele (ar133:W381 ~stop) of 
Sel-12 was a recessive supressor of lin-12 and might corre- 
spond to presenilin 1-374 on the viewpoint of their truncation 
in size and homology. Thus, taken together with the evolu- 
tional conservation between presenilin I and Sel-12, the pre- 
sent finding provides the supporting evidence for the recent 
hypothesis that the presenilin family may function as a sup- 
pressor and/or enhancer of the lin-12/Notch family, receptors 
for intercellular signals to specify cell fates [15]. 
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